The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Identifieur interne : 000281 ( PubMed/Checkpoint ); précédent : 000280; suivant : 000282The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Auteurs : Michael Michael ; Rocio Garcia-Carbonero [Espagne] ; Matthias M. Weber [Allemagne] ; Catherine Lombard-Bohas [France] ; Christos Toumpanakis [Royaume-Uni] ; Rodney J. Hicks [Australie]Source :
- The oncologist [ 1549-490X ] ; 2017.
Abstract
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors, with >50% of cases involving the gastrointestinal system or pancreas. Somatostatin analogs (SSAs) are used for treating NET-related secretory syndromes and, more recently, for their antiproliferative effects. We conducted a systematic review of published literature on the antiproliferative efficacy and safety of the SSA lanreotide Autogel in the management of NETs to gain a fuller understanding of the evidence and identify future areas of research.
DOI: 10.1634/theoncologist.2016-0305
PubMed: 28220021
Affiliations:
- Allemagne, Australie, Espagne, France, Royaume-Uni
- Angleterre, Auvergne-Rhône-Alpes, Communauté de Madrid, Grand Londres, Rhénanie-Palatinat, Rhône-Alpes
- Londres, Lyon, Madrid, Mayence
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28220021Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.</title><author><name sortKey="Michael, Michael" sort="Michael, Michael" uniqKey="Michael M" first="Michael" last="Michael">Michael Michael</name><affiliation><nlm:affiliation>Neuorendocrine Service & Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia Michael.Michael@petermac.org.</nlm:affiliation><wicri:noCountry code="subField">Australia Michael.Michael@petermac.org.</wicri:noCountry></affiliation></author><author><name sortKey="Garcia Carbonero, Rocio" sort="Garcia Carbonero, Rocio" uniqKey="Garcia Carbonero R" first="Rocio" last="Garcia-Carbonero">Rocio Garcia-Carbonero</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario Doce de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Doce de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Weber, Matthias M" sort="Weber, Matthias M" uniqKey="Weber M" first="Matthias M" last="Weber">Matthias M. Weber</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital Mainz, Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital Mainz, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Lombard Bohas, Catherine" sort="Lombard Bohas, Catherine" uniqKey="Lombard Bohas C" first="Catherine" last="Lombard-Bohas">Catherine Lombard-Bohas</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Édouard-Herriot, Fédération des spécialités digestives, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Édouard-Herriot, Fédération des spécialités digestives, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Toumpanakis, Christos" sort="Toumpanakis, Christos" uniqKey="Toumpanakis C" first="Christos" last="Toumpanakis">Christos Toumpanakis</name><affiliation wicri:level="3"><nlm:affiliation>Neuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neuroendocrine Tumour Unit, Royal Free Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Hicks, Rodney J" sort="Hicks, Rodney J" uniqKey="Hicks R" first="Rodney J" last="Hicks">Rodney J. Hicks</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Imaging & Neuroendocrine Service & Molecular Imaging and Targeted Therapeutics Laboratory, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Imaging & Neuroendocrine Service & Molecular Imaging and Targeted Therapeutics Laboratory, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne</wicri:regionArea><wicri:noRegion>East Melbourne</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28220021</idno><idno type="pmid">28220021</idno><idno type="doi">10.1634/theoncologist.2016-0305</idno><idno type="wicri:Area/PubMed/Corpus">000F39</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F39</idno><idno type="wicri:Area/PubMed/Curation">000F36</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F36</idno><idno type="wicri:Area/PubMed/Checkpoint">000F36</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.</title><author><name sortKey="Michael, Michael" sort="Michael, Michael" uniqKey="Michael M" first="Michael" last="Michael">Michael Michael</name><affiliation><nlm:affiliation>Neuorendocrine Service & Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia Michael.Michael@petermac.org.</nlm:affiliation><wicri:noCountry code="subField">Australia Michael.Michael@petermac.org.</wicri:noCountry></affiliation></author><author><name sortKey="Garcia Carbonero, Rocio" sort="Garcia Carbonero, Rocio" uniqKey="Garcia Carbonero R" first="Rocio" last="Garcia-Carbonero">Rocio Garcia-Carbonero</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario Doce de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Doce de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Weber, Matthias M" sort="Weber, Matthias M" uniqKey="Weber M" first="Matthias M" last="Weber">Matthias M. Weber</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital Mainz, Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Hospital Mainz, Mainz</wicri:regionArea><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation></author><author><name sortKey="Lombard Bohas, Catherine" sort="Lombard Bohas, Catherine" uniqKey="Lombard Bohas C" first="Catherine" last="Lombard-Bohas">Catherine Lombard-Bohas</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Édouard-Herriot, Fédération des spécialités digestives, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Édouard-Herriot, Fédération des spécialités digestives, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Toumpanakis, Christos" sort="Toumpanakis, Christos" uniqKey="Toumpanakis C" first="Christos" last="Toumpanakis">Christos Toumpanakis</name><affiliation wicri:level="3"><nlm:affiliation>Neuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neuroendocrine Tumour Unit, Royal Free Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Hicks, Rodney J" sort="Hicks, Rodney J" uniqKey="Hicks R" first="Rodney J" last="Hicks">Rodney J. Hicks</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Imaging & Neuroendocrine Service & Molecular Imaging and Targeted Therapeutics Laboratory, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Imaging & Neuroendocrine Service & Molecular Imaging and Targeted Therapeutics Laboratory, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne</wicri:regionArea><wicri:noRegion>East Melbourne</wicri:noRegion></affiliation></author></analytic><series><title level="j">The oncologist</title><idno type="eISSN">1549-490X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neuroendocrine tumors (NETs) are a heterogeneous group of tumors, with >50% of cases involving the gastrointestinal system or pancreas. Somatostatin analogs (SSAs) are used for treating NET-related secretory syndromes and, more recently, for their antiproliferative effects. We conducted a systematic review of published literature on the antiproliferative efficacy and safety of the SSA lanreotide Autogel in the management of NETs to gain a fuller understanding of the evidence and identify future areas of research.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28220021</PMID><DateCreated><Year>2017</Year><Month>02</Month><Day>21</Day></DateCreated><DateRevised><Year>2017</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-490X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The oncologist</Title><ISOAbbreviation>Oncologist</ISOAbbreviation></Journal><ArticleTitle>The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.</ArticleTitle><Pagination><MedlinePgn>272-285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2016-0305</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuroendocrine tumors (NETs) are a heterogeneous group of tumors, with >50% of cases involving the gastrointestinal system or pancreas. Somatostatin analogs (SSAs) are used for treating NET-related secretory syndromes and, more recently, for their antiproliferative effects. We conducted a systematic review of published literature on the antiproliferative efficacy and safety of the SSA lanreotide Autogel in the management of NETs to gain a fuller understanding of the evidence and identify future areas of research.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Searches were conducted in PubMed up to March 16, 2016, and in the proceedings of four congresses from 2013 to 2016.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Screening of 1,132 publications identified in the searches found 40 relevant publications, including 27 full-length publications and 13 congress abstracts. Twenty-four of these publications reported antiproliferative efficacy data for lanreotide Autogel. The CLARINET study showed that 120 mg lanreotide Autogel every 4 weeks improves progression-free survival (PFS) in patients with gastroenteropancreatic (GEP)-NETs, with grade 1 or grade 2 (Ki-67 <10%) disease, providing class I evidence of its antiproliferative effects. The CLARINET open-label extension study reported a median PFS of 32.8 months with lanreotide Autogel. Other smaller studies generally support CLARINET.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Current clinical evidence shows that lanreotide Autogel has good antiproliferative activity with favorable safety and tolerability in patients with GEP-NETs, suggesting it should be considered as an early first-line treatment in this population. Further studies are needed to assess the potential benefits of higher doses and the use of lanreotide Autogel in combination therapy and as maintenance therapy in the absence of disease progression following other therapies. The Oncologist 2017;22:272-285 IMPLICATIONS FOR PRACTICE: This review presents the current clinical evidence for the antiproliferative activity of lanreotide Autogel in patients with midgut or pancreatic neuroendocrine tumors (NETs) and shows its effectiveness, safety, and tolerability in these patient populations. By systematically presenting all the clinical evidence, the review adds to existing publications by discussing results in a broad range of settings. The review also indicates future directions for investigation of the use of lanreotide Autogel in NETs originating in other locations, in combination therapy, or as maintenance therapy in progressive disease.</AbstractText><CopyrightInformation>© AlphaMed Press 2017.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michael</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuorendocrine Service & Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia Michael.Michael@petermac.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Carbonero</LastName><ForeName>Rocio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital Universitario Doce de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Matthias M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>University Hospital Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombard-Bohas</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hôpital Édouard-Herriot, Fédération des spécialités digestives, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toumpanakis</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hicks</LastName><ForeName>Rodney J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Cancer Imaging & Neuroendocrine Service & Molecular Imaging and Targeted Therapeutics Laboratory, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncologist</MedlineTA><NlmUniqueID>9607837</NlmUniqueID><ISSNLinking>1083-7159</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neuroendocrinology. 2004;80(6):394-424</RefSource><PMID Version="1">15838182</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 1998 Sep;93(9):1468-71</RefSource><PMID Version="1">9732927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Compr Canc Netw. 2009 Jul;7(7):712-47</RefSource><PMID Version="1">19635226</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gut. 1996 Aug;39(2):279-83</RefSource><PMID Version="1">8977344</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2006 Dec;17(12):1733-42</RefSource><PMID Version="1">16801334</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2003 Dec;10(4):451-8</RefSource><PMID Version="1">14713257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Rev. 2004 Jun;25(3):458-511</RefSource><PMID Version="1">15180952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2010 Feb 1;16(3):978-85</RefSource><PMID Version="1">20103666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2009 Jun;50(6):858-64</RefSource><PMID Version="1">19443590</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jun 20;26(18):3063-72</RefSource><PMID Version="1">18565894</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2003 Dec;10(4):459-62</RefSource><PMID Version="1">14713258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virchows Arch. 2002 May;440(5):461-75</RefSource><PMID Version="1">12021920</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2003 Aug;44(8):1315-21</RefSource><PMID Version="1">12902423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Adv Hematol Oncol. 2016 May;14 (5 Suppl 7):6-7</RefSource><PMID Version="1">27168103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surg Today. 1997;27(2):112-9</RefSource><PMID Version="1">9017986</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jul 17;371(3):224-33</RefSource><PMID Version="1">25014687</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2006 Mar;17(3):461-6</RefSource><PMID Version="1">16364959</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Jul 15;21(14 ):2689-96</RefSource><PMID Version="1">12860945</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Neuroendocrinol. 2013 Aug;34(3):228-52</RefSource><PMID Version="1">23872332</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroendocrinology. 2014;100(4):265-77</RefSource><PMID Version="1">25300695</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroendocrinology. 2010;91(3):268-78</RefSource><PMID Version="1">20389030</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Mar 1;29(7):934-43</RefSource><PMID Version="1">21263089</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2001 Sep;12(9):1295-300</RefSource><PMID Version="1">11697843</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2010 Sep;17(9):2427-43</RefSource><PMID Version="1">20217257</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Oct 1;27(28):4656-63</RefSource><PMID Version="1">19704057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 1989 Feb;68(2):239-46</RefSource><PMID Version="1">2563730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2000 Sep;11(9):1127-30</RefSource><PMID Version="1">11061606</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2014 Sep;11(9):501</RefSource><PMID Version="1">25073004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2013 Sep 20;13:427</RefSource><PMID Version="1">24053191</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88</RefSource><PMID Version="1">19845567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2014 Jan 1;20(1):246-52</RefSource><PMID Version="1">24240109</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2017 Feb;22(2):165-172</RefSource><PMID Version="1">28179574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Endocrinol Invest. 2011 Oct;34(9):692-7</RefSource><PMID Version="1">22067307</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroendocrinology. 2016;103(2):186-94</RefSource><PMID Version="1">26731334</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroendocrinology. 2016;103(2):172-85</RefSource><PMID Version="1">26731013</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncology. 2001;60(2):141-5</RefSource><PMID Version="1">11244329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2016 Mar;23 (3):191-9</RefSource><PMID Version="1">26743120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Metastasis Rev. 2015 Dec;34(4):823-42</RefSource><PMID Version="1">26433592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2011 Jul;34(2):235-42</RefSource><PMID Version="1">21585408</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HPB (Oxford). 2010 Aug;12(6):361-79</RefSource><PMID Version="1">20662787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2005 Apr 7;11(13):2041-4</RefSource><PMID Version="1">15801004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1987 Oct;5(10):1502-22</RefSource><PMID Version="1">2443618</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Nov 15;107(10 ):2474-81</RefSource><PMID Version="1">17054107</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S17-25</RefSource><PMID Version="1">22005113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2012;17 (6):747-55</RefSource><PMID Version="1">22628056</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 1997 Oct;8(10 ):1041-4</RefSource><PMID Version="1">9402179</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res Treat. 2011 Sep;43(3):181-8</RefSource><PMID Version="1">22022296</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2003 Feb 15;97(4):934-59</RefSource><PMID Version="1">12569593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1999 Mar 18;340(11):858-68</RefSource><PMID Version="1">10080850</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2015 Jul 04;15:495</RefSource><PMID Version="1">26138480</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2003 Dec;2(12):999-1017</RefSource><PMID Version="1">14654798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Endocrinol. 2008 Oct;159(4):475-82</RefSource><PMID Version="1">18662970</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Digestion. 1996;57 Suppl 1:77-80</RefSource><PMID Version="1">8813476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 1994;30A(10 ):1590-1</RefSource><PMID Version="1">7833124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1993 Jul 1;72(1):244-8</RefSource><PMID Version="1">8389666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2014 Nov;55(11):1786-90</RefSource><PMID Version="1">25286923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2008 Jul 1;113(1):5-21</RefSource><PMID Version="1">18473355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2004 Jun;15(6):966-73</RefSource><PMID Version="1">15151956</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2013 Feb;40(1):56-68</RefSource><PMID Version="1">23391113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2001 May;37(8):1014-9</RefSource><PMID Version="1">11334727</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Digestion. 1993;54 Suppl 1:72-5</RefSource><PMID Version="1">8359572</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2006 Sep;13(3):955-62</RefSource><PMID Version="1">16954443</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 1993;32(2):217-23</RefSource><PMID Version="1">7686764</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2004 Apr;1014:121-31</RefSource><PMID Version="1">15153426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 2000 Nov;95(11):3276-81</RefSource><PMID Version="1">11095353</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1999 Apr;17 (4):1111</RefSource><PMID Version="1">10561168</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Case Rep Oncol. 2014 Dec 04;7(3):815-8</RefSource><PMID Version="1">25580103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Oncol. 2000 Aug;23 (4):412-5</RefSource><PMID Version="1">10955874</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncol Rep. 1994 Jan;1(1):129-31</RefSource><PMID Version="1">21607321</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Clin Cancer Res. 2010 Mar 02;29:19</RefSource><PMID Version="1">20196864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1998 Sep 5;352(9130):799-805</RefSource><PMID Version="1">9737302</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Thorac Cardiovasc Surg. 1999 Aug;5(4):211-9</RefSource><PMID Version="1">10508944</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Pathol. 2000 Jul;114(1):100-10</RefSource><PMID Version="1">10884805</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chest. 2001 Jan;119(1):14-8</RefSource><PMID Version="1">11157578</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Rev. 2003 Feb;24(1):28-47</RefSource><PMID Version="1">12588807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gut. 1998 Aug;43(2):223-8</RefSource><PMID Version="1">10189848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Case Rep Oncol. 2014 Sep 26;7(3):673-80</RefSource><PMID Version="1">25408662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Digestion. 1999 Sep-Oct;60(5):469-76</RefSource><PMID Version="1">10473972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Gastroenterol Hepatol. 2013 Feb;25(2):232-8</RefSource><PMID Version="1">23108416</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ANZ J Surg. 2002 Sep;72 (9):635-8</RefSource><PMID Version="1">12269913</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Heart Valve Dis. 2013 May;22(3):400-7</RefSource><PMID Version="1">24151767</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AAPS J. 2016 May;18(3):703-12</RefSource><PMID Version="1">26908127</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2010 Nov 30;18(1):1-11</RefSource><PMID Version="1">20943719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroendocrinology. 2009;90(2):167-83</RefSource><PMID Version="1">19077417</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiproliferative</Keyword><Keyword MajorTopicYN="N">Gastroenteropancreatic neuroendocrine tumors</Keyword><Keyword MajorTopicYN="N">Lanreotide</Keyword><Keyword MajorTopicYN="N">Neuroendocrine tumors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28220021</ArticleId><ArticleId IdType="pii">theoncologist.2016-0305</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.2016-0305</ArticleId><ArticleId IdType="pmc">PMC5344642</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Espagne</li><li>France</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Auvergne-Rhône-Alpes</li><li>Communauté de Madrid</li><li>Grand Londres</li><li>Rhénanie-Palatinat</li><li>Rhône-Alpes</li></region><settlement><li>Londres</li><li>Lyon</li><li>Madrid</li><li>Mayence</li></settlement></list><tree><noCountry><name sortKey="Michael, Michael" sort="Michael, Michael" uniqKey="Michael M" first="Michael" last="Michael">Michael Michael</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Garcia Carbonero, Rocio" sort="Garcia Carbonero, Rocio" uniqKey="Garcia Carbonero R" first="Rocio" last="Garcia-Carbonero">Rocio Garcia-Carbonero</name></region></country><country name="Allemagne"><region name="Rhénanie-Palatinat"><name sortKey="Weber, Matthias M" sort="Weber, Matthias M" uniqKey="Weber M" first="Matthias M" last="Weber">Matthias M. Weber</name></region></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Lombard Bohas, Catherine" sort="Lombard Bohas, Catherine" uniqKey="Lombard Bohas C" first="Catherine" last="Lombard-Bohas">Catherine Lombard-Bohas</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Toumpanakis, Christos" sort="Toumpanakis, Christos" uniqKey="Toumpanakis C" first="Christos" last="Toumpanakis">Christos Toumpanakis</name></region></country><country name="Australie"><noRegion><name sortKey="Hicks, Rodney J" sort="Hicks, Rodney J" uniqKey="Hicks R" first="Rodney J" last="Hicks">Rodney J. Hicks</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000281 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000281 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28220021
|texte= The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28220021" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |